Treatment of cytomegalovirus (CMV) infections after stem cell transplantation (SCT) does not always lead to a rapid viral response. The causes of treatment failure may be either viral resistance or immunological failure to control viral replication. This study investigated the response to pre-emptive treatment in CMV infections in order to define risk factors for treatment failure, including the role of antiviral resistance.
Methods
Adult recipients of allogeneic T-cell depleted SCT were studied retrospectively (n=92). CMV infections were treated with (val)ganciclovir according to a CMV DNA-load-based pre-emptive strategy. Treatment failure was defined as a CMV DNA load of 1,000 copies/ml or more after at least 2 weeks of treatment. Resistance was analysed by nucleotide sequence analysis of the UL97 and UL54 genes in the first CMV DNA-positive sample and in samples during treatment failure.
Results
Treatment failure occurred in 26 of the 47 pre-emptively treated patients (55%) and in 39 of 86 (45%) treatment episodes. The risk of treatment failure was increased during first treatment episodes (P=0.01) and during the use of immunosuppressive medication (P=0.02). Antiviral resistance was found in only 1 patient (4%) with treatment failure.
Conclusions
A slow response to pre-emptive antiviral treatment occurred frequently in CMV infections in SCT recipients. Antiviral resistance was observed but played a minor role in treatment failure.
References
1.
SchulenburgA., Watkins-RiedelT., GreinixH.T.CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant2001; 28: 765–768.
2.
VerkruyseL.A., StorchG.A., DevineS.M., DipersioJ.F., VijR.Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant2006; 37: 51–56.
3.
CortezK.J., FischerS.H., FahleG.A.Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis2003; 188: 967–972.
4.
GhaffariS.H., ObeidiN., DehghanM.Monitoring of cytomegalovirus reactivation in bone marrow transplant recipients by real-time PCR. Pathol Oncol Res2008; 14: 399–409.
5.
van der HeidenP.L., KalpoeJ.S., BargeR.M.Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant2006; 37: 693–698.
6.
NicholsW.G., CoreyL., GooleyT.Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood2001; 97: 867–874.
7.
KalpoeJ.S., van der HeidenP.L., VaessenN.Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant2007; 40: 137–143.
8.
BargeR.M., BrouwerR.E., BeersmaM.F.Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant2001; 27: 1053–1058.
9.
BargeR.M., OsantoS., MarijtW.A.Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol2003; 31: 865–872.
10.
KalpoeJ.S., KroesA.C., de JongM.D.Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol2004; 42: 1498–1504.
11.
LjungmanP., GriffithsP., PayaC.Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis2002; 34: 1094–1097.
12.
van der BeekM.T., BergerS.P., VossenA.C.Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation2010; 89: 320–326.
13.
ChouS.Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol2008; 18: 233–246.
14.
PosthumaC.C., van der BeekM.T., van der Blij-de BrouwerC.S.Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus. J Clin Virol2011; 51: 25–30.
15.
EmeryV.C., CopeA.V., BowenE.F., GorD., GriffithsP.D.The dynamics of human cytomegalovirus replication in vivo. J Exp Med1999; 190: 177–182.
16.
BoivinG., BelangerR., DelageR.Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol2000; 38: 4356–4360.
17.
HantzS., Garnier-GeoffroyF., MazeronM.C.Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother2010; 65: 2628–2640.
18.
GilbertC., RoyJ., BelangerR.Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother2001; 45: 3669–3671.
19.
AlliceT., BuscaA., LocatelliF.Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother2009; 63: 600–608.
20.
BoivinG., GoyetteN., GilbertC., CovingtonE.Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol2005; 77: 425–429.
21.
EriceA., Gil-RodaC., PerezJ.L.Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis1997; 175: 1087–1092.
22.
LurainN.S., ChouS.Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev2010; 23: 689–712.
23.
GernaG., LilleriD., ZeccaM.Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica2005; 90: 526–533.
24.
AlmyroudisN.G., JakubowskiA., JaffeD.Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis2007; 9: 286–294.
25.
GratamaJ.W., BoeckhM., NakamuraR.Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood2010; 116: 1655–1662.
